Why the study?
To investigate novel potential biomarkers for the antidiastole of tuberculous pleural effusion from malignant pleural effusion.
Can proteome analysis identify biomarkers to differentiate tuberculous from malignant pleural effusion?
Can proteome analysis identify biomarkers to differentiate tuberculous from malignant pleural effusion?
A combination of fibronectin, leukotriene-A4 hydrolase, and cathepsin G may serve as a potential biomarker panel to differentiate tuberculous from malignant pleural effusion.
Hypothesis-generating for pleural effusion differentiation; prospective validation required before any clinical consideration.
AIM: To investigate novel potential biomarkers for antidiastole of tuberculous pleural effusion (TPE) from malignant pleural effusion (MPE). MATERIALS & METHODS: iTRAQTM-coupled LC-MS/MS were applied to analyze the proteome of TPE and MPE samples. The candidate proteins were verified by enzyme-linked immunosorbent assay. RESULTS: A total of 432 differential proteins were identified. Enzyme-linked immunosorbent assay revealed significantly higher levels of fibronectin (FN) and cathepsin G (CTSG) in MPE than in TPE, but lower levels of leukotriene-A4 hydrolase (LTA4H). The receiver operator characteristic values were 0.285 for FN, 0.64 for LTA4H, 0.337 for CTSG and 0.793 for a combination of these candidate markers. CONCLUSION: FN, LTA4H and CTSG were identified as potential biomarkers to differentiate TPE from MPE and their combination exhibited higher diagnostic capacity.
No takes yet. Share an insight, caveat, or question.
Shi et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: